< Back to Industry Collaborators
Funded by: Vertex Pharmaceuticals Inc.
Overview: The study examined the impact of Cystic Fibrosis Transmembrane Conductance Regulator Modulators (CFTRm) on healthcare resource utilization (HCRU) for individuals with cystic fibrosis (CF) in Wales. It aimed to assess hospitalizations, general practitioner (GP) visits, prescriptions, and the use of intravenous antibiotics before and after the initiation of CFTRm treatments, leveraging real-world data.
Why SAIL was valuable:
- SAIL allowed Linkage of healthcare data from the United Kingdom Cystic Fibrosis Registry (UKCFR) and electronic health records (EHRs) to enable a complete view of patients’ healthcare journeys.
- SAIL allowed researchers to track HCRU over extended periods before and after CFTRm initiation.
- SAIL maintained patient privacy while enabling robust data analysis for meaningful insights.
Results:
- Hospitalization rates dropped significantly after CFTRm initiation (1.78 events/year to 0.89 events/year in the broader cohort, and from 1.99 to 0.60 events/year for those using ELX/TEZ/IVA).
- Hospital stays lengths decreased from 15.2 days/year to 7.4 days/year post-CFTRm initiation.
- GP visit rates remained stable, with approximately 31 visits annually.
- Prescription rates increased slightly post-CFTRm initiation, reflecting better adherence to ongoing treatment regimens.
- The duration and frequency of intravenous antibiotics use showed minor reductions, highlighting potential improvements in symptom management.